BROWN RUDNICK LLP for HOSPIRA, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
S. 1413: FDA User Fee Protection Act; H.R. 2725: FDA Safety Over Sequestration Act of 2013; PL 113-67: The Bipartisan Budget Act of 2013; H.R. 3547: 2014 Consolidated Appropriations Act PHA; PL113-54: Drug Quality and Security Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BOWLIN | — |
| LISA LAYMAN New | — |
| HENRY W MENN | — |
Pharmacy PHA
Issues relating to generic drug labeling; S. 959: The Pharmaceutical Quality, Security and Accountability Act; H.R. 3204: The Compounding Clarity Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BOWLIN | — |
| LISA LAYMAN New | — |
| HENRY W MENN | — |
Health Issues HCR
Issues relating to drug and nutrient shortages; P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 232: Medical Device Access and Innovation Protection Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BOWLIN | Secr for Congr & Intgv Affairs, Dept. Labor 01-02 |
| LISA LAYMAN | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | Min SD & Counsel, Cmte on Vet Affairs (04) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.